Product Description
These 'ready-made' CAR T cells have been made using a new technique called Base Editing to modify their DNA code and have been given the code name 'BE CAR-33'. This technique allows them to work after chemotherapy and also disarms them to prevent effects against normal cells. (Sourced from: https://clinicaltrials.gov/study/NCT05942599)
Mechanisms of Action: CAR-T, CD33
Novel Mechanism: Yes
Modality: Allogeneic CAR-T
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Great Ormond Street Hospital for Children NHS Foundation Trust
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Acute Myeloid Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05942599 |
CARAML | P1 |
Active, not recruiting |
Acute Myeloid Leukemia |
2026-06-01 |
2026-01-15 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|